BIOLOGICAL · Unmapped registry intervention
9 Peptides from Her-2/neu, CEA, & CTA
Find medicine records ·
Find other trials using this name
Clinical trial
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
NCT00892567
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedEvaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Neoplasmsunresolved
Interventions
9 Peptides from Her-2/neu, CEA, & CTABIOLOGICAL
Sponsors & collaborators
Craig L Slingluff, Jrlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00892567 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.